Recently, evidence shows that GnRH analogues, by inhibiting the stimulation of gonadotrophins and thus ovarian cellular turnover, could decrease the chance of cellular destruction during gonadotoxic cancer treatments [28], although other mechanisms are also at play. Here, GNRH1 is linked to cancer.